Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Diana Bradford

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Current Treatment Options in Oncology|March 18, 2015
Current treatment options for malignant peripheral nerve sheath tumorsDiana Bradford, AeRang Kim
Current Opinion in Pediatrics|January 2, 2023
FDA regulatory considerations for the review of drugs intended to treat pediatric cancers and rare tumorsDiana Bradford, Harpreet Singh, Martha Donoghue
Expert Opinion on Orphan Drugs|August 9, 2020
Developing therapies for rare tumors: opportunities, challenges and progressDiana Bradford, Karlyne M Reilly, Brigitte C Widemann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2026
Selpercatinib and the Crossover Conundrum: Potential Impact of Postprogression Therapies on Overall SurvivalElizabeth S Duke, Diana Bradford, Arup K Sinha, et al.
The Oncologist|April 10, 2020
FDA Accelerated Approval of Pembrolizumab for Recurrent Locally Advanced or Metastatic Merkel Cell CarcinomaDiana Bradford, Suzanne Demko, Susan Jin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 15, 2024
Considering Functional Outcomes as Efficacy Endpoints in Pediatric Low-Grade Glioma Clinical Trials: An FDA Educational SymposiumJason Fangusaro, Robert A Avery, Michael J Fisher, et al.
Journal of Neuro-Oncology|June 22, 2021
US Food and Drug Administration regulatory updates in neuro-oncologyGautam U Mehta, Amy K Barone, Diana Bradford, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 25, 2024
US Food and Drug Administration Approval Summary: Eflornithine for High-Risk Neuroblastoma After Prior Multiagent, Multimodality TherapyElizabeth S Duke, Diana Bradford, Arup K Sinha, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 25, 2023
FDA Approval Summary: Alpelisib for PIK3CA-Related Overgrowth SpectrumSonia Singh, Diana Bradford, Xiaoxue Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 28, 2021
FDA Approval Summary: Pralsetinib for the Treatment of Lung and Thyroid Cancers With <i>RET</i> Gene Mutations or FusionsJanice Kim, Diana Bradford, Erin Larkins, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Current Treatment Options in Oncology|March 18, 2015
Current treatment options for malignant peripheral nerve sheath tumorsDiana Bradford, AeRang Kim
Current Opinion in Pediatrics|January 2, 2023
FDA regulatory considerations for the review of drugs intended to treat pediatric cancers and rare tumorsDiana Bradford, Harpreet Singh, Martha Donoghue
Expert Opinion on Orphan Drugs|August 9, 2020
Developing therapies for rare tumors: opportunities, challenges and progressDiana Bradford, Karlyne M Reilly, Brigitte C Widemann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2026
Selpercatinib and the Crossover Conundrum: Potential Impact of Postprogression Therapies on Overall SurvivalElizabeth S Duke, Diana Bradford, Arup K Sinha, et al.
The Oncologist|April 10, 2020
FDA Accelerated Approval of Pembrolizumab for Recurrent Locally Advanced or Metastatic Merkel Cell CarcinomaDiana Bradford, Suzanne Demko, Susan Jin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 15, 2024
Considering Functional Outcomes as Efficacy Endpoints in Pediatric Low-Grade Glioma Clinical Trials: An FDA Educational SymposiumJason Fangusaro, Robert A Avery, Michael J Fisher, et al.
Journal of Neuro-Oncology|June 22, 2021
US Food and Drug Administration regulatory updates in neuro-oncologyGautam U Mehta, Amy K Barone, Diana Bradford, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 25, 2024
US Food and Drug Administration Approval Summary: Eflornithine for High-Risk Neuroblastoma After Prior Multiagent, Multimodality TherapyElizabeth S Duke, Diana Bradford, Arup K Sinha, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 25, 2023
FDA Approval Summary: Alpelisib for PIK3CA-Related Overgrowth SpectrumSonia Singh, Diana Bradford, Xiaoxue Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 28, 2021
FDA Approval Summary: Pralsetinib for the Treatment of Lung and Thyroid Cancers With <i>RET</i> Gene Mutations or FusionsJanice Kim, Diana Bradford, Erin Larkins, et al.
Pageof 2